Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27910021 | 0.88 | PTGS2 (0.38) | LMNAPTGS2GRM5HSP90AA1HSP90AB1 | |
| SCHEMBL21610731 | 0.82 | GRM5 (0.34) | PTGS2GRM5TLR7ALDH1A1HPGD | |
| SCHEMBL77644 | 0.78 | ALDH1A1 (0.49) | LMNAGRM5MEN1KMT2AMAPT | |
| SCHEMBL10245083 | 0.74 | ALDH1A1 (0.40) | GRM5MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19309250 | 0.74 | ALDH1A1 (0.36) | GRM5MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11351815 | 0.74 | ALDH1A1 (0.36) | GRM5MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6266188 | 0.73 | MEN1 (0.35) | LMNAGRM5HSP90AA1HSP90AB1MEN1 | |
| SCHEMBL6137289 | 0.73 | IDH1 (0.36) | LMNAHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL533653 | 0.73 | MEN1 (0.35) | LMNAPTGS2GRM5HSP90AA1HSP90AB1 | |
| SCHEMBL29754794 | 0.73 | MEN1 (0.36) | LMNAHSP90AA1HSP90AB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994105-A | Novel pyrazole ester compound as well as preparation method and application thereof | 安阳师范学院 | 2024-11-22 | — | — | CN | claimed |
| CN-114634456-A | 5-nitroimino-4H-1, 2, 4-triazole compound and preparation method and application thereof | 赣南师范大学 | 2022-06-17 | — | — | CN | claimed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| CN-118994105-A | Novel pyrazole ester compound as well as preparation method and application thereof | 安阳师范学院 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4289842-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2023-12-13 | — | — | EP | disclosed |
| EP-1110956-B1 | The use of 5-carboxanilido-2,4-bis-trifluoromethylthiazoles to control rice blast | DOW AGROSCIENCES LLC (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| CN-1355810-A | Prodrugs of thrombin inhibitors | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| US-6372769-B1 | APPLYING FUNGICIDES TO RICE | DOW AGROSCIENCES LLC | 2002-04-16 | — | — | US | disclosed |
| EP-1110956-A1 | 5-carboxanilido-2,4-bis-trifluoromethylthiazoles and their use to control rice blast | ROHM AND HAAS COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0371950-B1 | Substituted thiazoles and their use as fungicides | MONSANTO CO (US) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | LMNA 3056/4885PTGS2 283/4885GRM5 315/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | LMNA 3056/4885PTGS2 283/4885GRM5 315/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | LMNA 2851/4885PTGS2 723/4885GRM5 214/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | LMNA 1296/4885PTGS2 1009/4885GRM5 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.